Subcutaneous Furosemide for Ambulatory Decongestion in Heart Failure: Outcomes From a High‐Risk Real‐World Cohort

Omar Jafar, Ann Harper, Angela Toepp, Amin Yehya

Open source

DOI
10.1002/clc.70514
Published
2026-11
Container
Clinical Cardiology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/clc.70514,
  title = {Subcutaneous Furosemide for Ambulatory Decongestion in Heart Failure: Outcomes From a High‐Risk Real‐World Cohort},
  author = {Omar Jafar and Ann Harper and Angela Toepp and Amin Yehya},
  year = {2026},
  journal = {Clinical Cardiology},
  doi = {10.1002/clc.70514},
  url = {https://doi.org/10.1002/clc.70514}
}

RIS

TY  - JOUR
TI  - Subcutaneous Furosemide for Ambulatory Decongestion in Heart Failure: Outcomes From a High‐Risk Real‐World Cohort
AU  - Omar Jafar
AU  - Ann Harper
AU  - Angela Toepp
AU  - Amin Yehya
PY  - 2026
JO  - Clinical Cardiology
DO  - 10.1002/clc.70514
UR  - https://doi.org/10.1002/clc.70514
ER  - 

APA

Jafar, O., Harper, A., Toepp, A., & Yehya, A. (2026). Subcutaneous Furosemide for Ambulatory Decongestion in Heart Failure: Outcomes From a High‐Risk Real‐World Cohort. Clinical Cardiology. https://doi.org/10.1002/clc.70514

Source records